Market Summary
USD9.32-0.29
Market Closed-3.02%
PACB Stock Price
PACB RSI Chart
PACB Valuation
PACB Price/Sales (Trailing)
PACB Profitability
PACB Fundamentals
PACB Revenue
PACB Earnings
Price Action
52 Week Range
3.8514.20
(Low)(High)
Last 7 days
11.5%
Last 30 days
6.3%
Last 90 days
16.2%
Trailing 12 Months
0.9%
PACB Financial Health
PACB Investor Care
Peers (Alternatives to Pacific Biosciences of California)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 39.3B | 6.8B | -5.76% | -1.62% | 31.3 | 5.73 | 8.37% | 3.64% |
ILMN | 34.4B | 4.6B | 10.80% | -36.26% | -7.81 | 7.51 | 1.28% | -677.95% |
MTD | 32.8B | 3.9B | 3.74% | 6.71% | 37.59 | 8.37 | 5.43% | 13.46% |
WAT | 17.9B | 3.0B | -3.60% | -7.13% | 25.24 | 6.01 | 6.68% | 2.15% |
PKI | 16.2B | 3.3B | 2.29% | -27.60% | 28.4 | 4.88 | -34.64% | -39.65% |
| MID-CAP | ||||||||
| SMALL-CAP | ||||||||
PACB | 2.0B | 128.3M | 6.27% | 0.87% | -6.41 | 15.69 | -1.69% | -73.40% |
ADPT | 1.1B | 185.3M | 4.81% | -31.55% | -5.67 | 6.12 | 20.06% | 3.42% |
QTRX | 401.5M | 105.5M | -5.95% | -61.12% | -4.15 | 3.8 | -4.55% | -67.63% |
NSTG | 401.3M | 127.3M | -3.95% | -71.99% | -2.52 | 3.15 | -12.28% | -38.43% |
BNGO | 323.9M | 27.8M | -13.39% | -53.59% | -2.44 | 11.65 | 54.62% | -83.06% |
CDXS | 250.7M | 138.6M | -19.03% | -80.42% | -7.46 | 1.81 | 32.30% | -57.86% |
HBIO | 126.7M | 113.3M | 13.22% | -43.77% | -13.31 | 1.12 | -4.68% | -3204.17% |
PSNL | 125.6M | 65.0M | -11.53% | -66.71% | -1.11 | 1.93 | -23.92% | -73.73% |
CSBR | 56.3M | 54.1M | -9.78% | -51.18% | 521 | 1.04 | 21.80% | -72.38% |
Financials for Pacific Biosciences of California
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -6.3% | 128,304,000 | 136,970,000 | 139,546,000 | 134,689,000 | 130,513,000 |
| Cost Of Revenue | 3.9% | 79,269,000 | 76,309,000 | 77,068,000 | 74,651,000 | 71,653,000 |
| Gross Profit | -19.2% | 49,035,000 | 60,661,000 | 62,478,000 | 60,038,000 | 58,860,000 |
| Operating Expenses | 3.1% | 356,231,000 | 345,449,000 | 347,122,000 | 314,286,000 | 269,295,000 |
| S&GA Expenses | 5.0% | 160,854,000 | 153,171,000 | 147,982,000 | 137,790,000 | 124,124,000 |
| R&D Expenses | 0.0% | 193,000,000 | 192,953,000 | 173,369,000 | 145,287,000 | 112,899,000 |
| EBITDA | -8.8% | -290,078,000 | -266,535,000 | -252,572,000 | - | - |
| EBITDA Margin | -16.2% | -2.26 | -1.95 | -1.88 | - | - |
| Earnings Before Taxes | -8.3% | -314,248,000 | -290,250,000 | -274,872,000 | - | - |
| EBT Margin | -15.6% | -2.45 | -2.12 | -2.04 | - | - |
| Interest Expenses | 1.2% | 14,690,000 | 14,521,000 | 14,530,000 | 14,438,000 | 12,530,000 |
| Net Income | -5.0% | -314,248,000 | -299,193,000 | -205,680,000 | -175,287,000 | -181,223,000 |
| Net Income Margin | -12.1% | -2.45 | -2.18 | -1.47 | -1.30 | - |
| Free Cahsflow | -12.4% | -279,961,000 | -249,041,000 | -223,574,000 | -176,273,000 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -2.9% | 1,767 | 1,819 | 1,876 | 1,937 | 2,007 |
| Current Assets | -6.8% | 852 | 914 | 970 | 1,029 | 1,101 |
| Cash Equivalents | 6.8% | 325 | 304 | 310 | 429 | 461 |
| Inventory | 15.8% | 50.00 | 43.00 | 36.00 | 30.00 | 25.00 |
| Net PPE | 6.2% | 42.00 | 39.00 | 38.00 | 36.00 | 33.00 |
| Goodwill | 0% | 410 | 410 | 410 | 410 | 410 |
| Liabilities | 1.0% | 1,204 | 1,192 | 1,194 | 1,202 | 1,216 |
| Current Liabilities | 222.5% | 263 | 82.00 | 84.00 | 61.00 | 72.00 |
| Shareholder's Equity | -10.2% | 563 | 627 | 682 | 735 | 791 |
| Retained Earnings | -5.8% | -1,532 | -1,447 | -1,370 | -1,299 | -1,218 |
| Additional Paid-In Capital | 0.9% | 2,100 | 2,081 | 2,058 | 2,038 | 2,010 |
| Shares Outstanding | 0.3% | 227 | 226 | 225 | 224 | 221 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -12.3% | -263 | -234 | -211 | -167 | -111 |
| Share Based Compensation | -1.2% | 79.00 | 80.00 | 89.00 | 86.00 | 73.00 |
| Cashflow From Investing | 14.4% | 116 | 101 | -244 | -644 | -678 |
| Cashflow From Financing | -5.0% | 10.00 | 10.00 | 307 | 309 | 1,170 |
Risks for PACB
What is the probability of a big loss on PACB?
100%
Probability that Pacific Biosciences of California stock will be more than 20% underwater in next one year
90%
Probability that Pacific Biosciences of California stock will be more than 30% underwater in next one year.
72.3%
Probability that Pacific Biosciences of California stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does PACB drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Pacific Biosciences of California was unfortunately bought at previous high price.
Drawdowns
Returns for PACB
Cumulative Returns on PACB
14.1%
10-Year Cumulative Returns
2.3%
7-Year Cumulative Returns
33.7%
5-Year Cumulative Returns
41.6%
3-Year Cumulative Returns
What are the long-term rolling returns for PACB?
FIve years rolling returns for Pacific Biosciences of California.
Annualized Returns
Which funds bought or sold PACB recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | unchanged | - | 279,915 | 964,087 | 0.01% |
2023-03-17 | American Portfolios Advisors | reduced | -1.48 | 38,948 | 171,486 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.04 | 54,862 | 187,862 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 107 | 6,000 | 8,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | 205,282 | 708,282 | -% |
2023-02-28 | Orin Green Financial, LLC | unchanged | - | 28,160 | 98,160 | 0.06% |
2023-02-27 | Parallax Volatility Advisers, L.P. | reduced | -99.45 | -1,046,880 | 8,123 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -2,300,000 | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 650 | 650 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -0.27 | 9,458,000 | 32,822,000 | 0.04% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Pacific Biosciences of California News
Schedule 13G FIlings of Pacific Biosciences of California
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital international investors | 2.7% | 6,099,681 | SC 13G/A | |
| Feb 13, 2023 | madrone capital partners, llc | 7.3% | 16,415,933 | SC 13G/A | |
| Feb 10, 2023 | nikko asset management americas, inc. | 6.26% | 14,166,193 | SC 13G/A | |
| Feb 10, 2023 | ark investment management llc | 11.36% | 25,691,681 | SC 13G/A | |
| Feb 10, 2023 | jackson square partners, llc | 6.64% | 15,005,177 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.97% | 20,279,035 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.2% | 18,534,459 | SC 13G/A | |
| Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 6.26% | 14,166,193 | SC 13G/A | |
| Jun 01, 2022 | madrone capital partners, llc | 6.0% | 13,415,933 | SC 13G | |
| Feb 14, 2022 | nikko asset management americas, inc. | 5.40% | 11,915,025 | SC 13G |
PACB Fair Value
Pacific Biosciences of California fair value in different scenarios
The table shows the Fair Value estimates for Pacific Biosciences of California for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 0.47 -94.96% | 0.50 -94.64% | 0.57 -93.88% | 0.69 -92.60% | 0.86 -90.77% |
| Current Inflation | 0.47 -94.96% | 0.50 -94.64% | 0.56 -93.99% | 0.66 -92.92% | 0.81 -91.31% |
| Very High Inflation | 0.47 -94.96% | 0.49 -94.74% | 0.54 -94.21% | 0.63 -93.24% | 0.75 -91.95% |
Historical Pacific Biosciences of California Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Pacific Biosciences of California
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 27, 2023 | PRE 14A | PRE 14A | |
| Mar 17, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Feb 28, 2023 | 10-K | Annual Report | |
| Feb 28, 2023 | S-8 | Employee Benefits Plan | |
| Feb 22, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for PACB
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-15 | Ericson William W. | sold | -67,114 | 8.9 | -7,541 | - |
2023-03-15 | Ericson William W. | acquired | 63,500 | 2.54 | 25,000 | - |
2023-03-03 | Kim Susan G. | sold | -47,892 | 9.493 | -5,045 | see remarks |
2023-03-03 | Farmer Michele | sold | -29,931 | 9.493 | -3,153 | see remarks |
2023-03-03 | Van Oene Mark | sold | -59,502 | 9.493 | -6,268 | see remarks |
2023-03-03 | HENRY CHRISTIAN O | sold | -130,709 | 9.493 | -13,769 | see remarks |
2023-03-02 | HENRY CHRISTIAN O | acquired | - | - | 594,687 | see remarks |
2023-03-02 | Van Oene Mark | acquired | - | - | 328,500 | see remarks |
2023-03-02 | Kim Susan G. | acquired | - | - | 164,200 | see remarks |
2023-03-02 | Eidel Jeff | acquired | - | - | 164,200 | see remarks |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
PACB Income Statement
2022-12-31Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) shares in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenue: | |||
| Total revenue | $ 128,304,000 | $ 130,513,000 | $ 78,893,000 |
| Cost of Revenue: | |||
| Amortization of intangible assets | 733,000 | 306,000 | |
| Loss on purchase commitment | 3,705,000 | ||
| Total cost of revenue | 79,269,000 | 71,653,000 | 46,327,000 |
| Gross profit | 49,035,000 | 58,860,000 | 32,566,000 |
| Operating Expense: | |||
| Research and development | 193,000,000 | 112,899,000 | 64,152,000 |
| Sales, general and administrative | 160,854,000 | 124,124,000 | 72,799,000 |
| Merger-related expenses | 31,129,000 | ||
| Change in fair value of contingent consideration | 2,377,000 | 1,143,000 | |
| Total operating expense | 356,231,000 | 269,295,000 | 136,951,000 |
| Operating loss | (307,196,000) | (210,435,000) | (104,385,000) |
| Gain from Reverse Termination Fee from Illumina | 98,000,000 | ||
| (Loss)/Gain from Continuation Advances from Illumina | (52,000,000) | 34,000,000 | |
| Interest expense | (14,690,000) | (12,530,000) | (267,000) |
| Other income, net | 7,638,000 | 93,000 | 2,055,000 |
| (Loss) income before benefit from income taxes | (314,248,000) | (274,872,000) | 29,403,000 |
| Benefit from income taxes | (93,649,000) | ||
| Net (loss) income | (314,248,000) | (181,223,000) | 29,403,000 |
| Other comprehensive (loss) income: | |||
| Unrealized (loss) gain on investments | (3,678,000) | (1,172,000) | 80,000 |
| Comprehensive (loss) income: | $ (317,926,000) | $ (182,395,000) | $ 29,483,000 |
| Net (loss) income per share: | |||
| Basic | $ (1.40) | $ (0.89) | $ 0.18 |
| Diluted | $ (1.40) | $ (0.89) | $ 0.17 |
| Weighted average shares outstanding used in calculating net (loss) income per share: | |||
| Basic | 224,550 | 204,136 | 165,187 |
| Diluted | 224,550 | 204,136 | 174,970 |
| Product [Member] | |||
| Revenue: | |||
| Total revenue | $ 108,699,000 | $ 113,505,000 | $ 65,424,000 |
| Cost of Revenue: | |||
| Cost of product revenue | 60,932,000 | 56,358,000 | 35,424,000 |
| Service and Other [Member] | |||
| Revenue: | |||
| Total revenue | 19,605,000 | 17,008,000 | 13,469,000 |
| Cost of Revenue: | |||
| Cost of service and other revenue | $ 13,899,000 | $ 14,989,000 | $ 10,903,000 |
PACB Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 325,089 | $ 460,725 |
| Investments | 447,229 | 583,675 |
| Accounts receivable, net | 18,786 | 24,241 |
| Inventory, net | 50,381 | 24,599 |
| Prepaid expenses and other current assets | 10,289 | 7,394 |
| Short-term restricted cash | 300 | 500 |
| Total current assets | 852,074 | 1,101,134 |
| Property and equipment, net | 41,580 | 32,504 |
| Operating lease right-of-use assets, net | 39,763 | 46,617 |
| Long-term restricted cash | 2,922 | 4,592 |
| Intangible assets, net | 410,245 | 410,979 |
| Goodwill | 409,974 | 409,974 |
| Other long-term assets | 10,528 | 1,170 |
| Total assets | 1,767,086 | 2,006,970 |
| Current liabilities | ||
| Accounts payable | 12,028 | 11,002 |
| Accrued expenses | 32,596 | 36,261 |
| Deferred revenue, current | 30,498 | 10,977 |
| Operating lease liabilities, current | 8,886 | 7,710 |
| Other liabilities, current | 7,233 | 5,759 |
| Contingent consideration liability, current | 172,094 | |
| Total current liabilities | 263,335 | 71,709 |
| Deferred revenue, non-current | 1,794 | 25,049 |
| Contingent consideration liability, non-current | 169,717 | |
| Operating lease liabilities, non-current | 41,070 | 49,970 |
| Convertible senior notes, net, non-current | 896,683 | 896,067 |
| Other liabilities, non-current | 1,300 | 3,471 |
| Total liabilities | 1,204,182 | 1,215,983 |
| Commitments and contingencies | ||
| Stockholders' equity | ||
| Preferred stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding | ||
| Common stock, $0.001 par value: Authorized 1,000,000 shares; issued and outstanding 226,505 and 220,978 shares at December 31, 2022 and December 31, 2021, respectively | 227 | 221 |
| Additional paid-in capital | 2,099,782 | 2,009,945 |
| Accumulated other comprehensive loss | (4,765) | (1,087) |
| Accumulated deficit | (1,532,340) | (1,218,092) |
| Total stockholders' equity | 562,904 | 790,987 |
| Total liabilities and stockholders' equity | $ 1,767,086 | $ 2,006,970 |